N@N

CRISPR-Cas technology: Balancing efficiency and safety

The article from ScienceDaily discusses a study published in the journal *Nature Communications* that explores the potential of using a common cold virus, specifically a modified version of the Coxsackievirus B3 (CVB3), as a treatment for glioblastoma, an aggressive form of brain cancer. Researchers at the University of California, San Diego, found that this virus can selectively infect and kill cancer cells while sparing healthy cells. The study showed that when the virus was injected directly into the tumors of mice with glioblastoma, it significantly reduced tumor size and extended survival rates. The virus works by triggering an immune response that not only attacks the cancer cells directly but also enhances the body's immune system to fight the tumor more effectively. This approach represents a novel oncolytic virotherapy, where viruses are engineered to target and destroy cancer cells, offering hope for a new treatment avenue for this otherwise hard-to-treat cancer.

Read the Full Science Daily Article at:
[ https://www.sciencedaily.com/releases/2024/12/241204114015.htm ]